Results 91 to 100 of about 104,915 (286)

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics

BMC Medical Genomics, 2018
Background With the advancement of next generation sequencing technology, researchers are now able to identify important variants and structural changes in DNA and RNA in cancer patient samples.
Jennifer D. Hintzsche, Minjae Yoo, Jihye Kim, Carol M. Amato, William A. Robinson, Aik Choon Tan   +5 more
doaj   +1 more source

Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial. [PDF]

, 2018
ObjectiveTo better understand the utility of using pain freedom and most bothersome headache-associated symptom (MBS) freedom as co-primary endpoints in clinical trials of acute migraine interventions.BackgroundAdhesive dermally applied microarray (ADAM)
Dodick, David W, Friedman, Deborah I, Gelfand, Amy A, Kellerman, Donald J, Schmidt, Peter C, Tepper, Stewart J   +5 more
core   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Alternative Administration of Antiretroviral Therapy in People with HIV Unable to Swallow: A Scoping Review

HIV/AIDS: Research and Palliative Care
Hilal Abdessamad,1 Christina Baroody,2,* Karolina Pogorzelski,3,* Wassim Jamaleddine,1,* Monicah Syomiti Kitonga,4 Habib Omar,5 Seth Adu Amankrah,5 Kristine Allen-Brown,5 Dima Dandachi1 1Division of Infectious Diseases, Department
Abdessamad H, Baroody C, Pogorzelski K, Jamaleddine W, Kitonga MS, Omar H, Amankrah SA, Allen-Brown K, Dandachi D   +8 more
doaj  

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

Journal of Experimental Pharmacology, 2020
Josuel Ora,1 Angelo Coppola,2 Mario Cazzola,3 Luigino Calzetta,4 Paola Rogliani1,3 1Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy; 2Division of Respiratory Medicine, San Filippo Neri Hospital, Rome, Italy; 3Department of ...
Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P   +4 more
doaj  

Setting up mother–infant pair lactation studies with biobanking for research according to regulatory requirements

British Journal of Clinical Pharmacology, EarlyView.
Within the ConcePTION project we set out to design two mother–infant pair studies collecting breast milk and plasma from the mother and plasma from the infant (for metformin and prednisolone) in order to demonstrate the premises and conditions for investigating potential drug transfer in association with breastfeeding.
Mats Hansson, Ida Björkgren, Jenny Svedenkrans, Helena Backman, Jarl Hellman, Linda Englund‐Ögge, Mikaela Magnusson, Inger Lindström, Andrea Wutte, Erica Sundell, Pawel Baranczewski, Laura Shaughnessy   +11 more
wiley   +1 more source

Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)

Journal of Experimental Pharmacology, 2020
Ravina Kullar,1 Mai-Chi N Tran,2,3 Ellie JC Goldstein4,5 1Expert Stewardship, Inc., Newport Beach, CA, USA; 2Pharmacy Department, Keck Medical Center of USC, Los Angeles, CA, USA; 3Clinica Juan Pablo Medical Group, Los Angeles, CA, USA; 4R.M.
Kullar R, Tran MCN, Goldstein EJC
doaj  

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. [PDF]

, 2015
BackgroundThis retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by evaluating the impact of prior activity and intervening time interval.MethodsEighty ...
Eng, C, Falchook, GS, Fu, S, Garrett, C, George, GC, Hess, K, Hong, DS, Janku, F, Karp, D, Kopetz, S, Kurzrock, R, Liu, X, Meric-Bernstam, F, Naing, A, Overman, MJ, Piha-Paul, SA, Raghav, K, Subbiah, V, Tsimberidou, AM, Wheler, JJ, Zinner, R   +20 more
core   +2 more sources